Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 10/20 | 0.70 |
| ▸ | RAB9A | P51151 | 10/20 | 0.70 |
| ▸ | GAA | P10253 | 5/20 | 0.70 |
| ▸ | MAPT | P10636 | 3/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.66 |
| ▸ | AGTR1 | P30556 | 5/20 | 0.62 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | PKM | P14618 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27178051 | 1.00 | NPC1 (0.70) | NPC1RAB9AGAAMAPTKMT2A | |
| SCHEMBL27178057 | 1.00 | NPC1 (0.70) | NPC1RAB9AGAAMAPTKMT2A | |
| SCHEMBL30826052 | 0.88 | NPC1 (0.69) | NPC1RAB9AGAAMAPTKMT2A | |
| SCHEMBL27178162 | 0.88 | NPC1 (0.69) | NPC1RAB9AGAAMAPTKMT2A | |
| SCHEMBL27178152 | 0.88 | NPC1 (0.69) | NPC1RAB9AGAAMAPTKMT2A | |
| SCHEMBL27178013 | 0.86 | NPC1 (0.58) | NPC1RAB9AGAAMAPTKMT2A | |
| SCHEMBL27178019 | 0.86 | NPC1 (0.58) | NPC1RAB9AGAAMAPTKMT2A | |
| SCHEMBL30826062 | 0.84 | NPC1 (0.58) | NPC1RAB9AGAAMAPTKMT2A | |
| SCHEMBL27178098 | 0.84 | NPC1 (0.58) | NPC1RAB9AGAAMAPTKMT2A | |
| SCHEMBL27178107 | 0.84 | NPC1 (0.58) | NPC1RAB9AGAAMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4580403-A2 | APYRASE INHIBITORS | Texas Crop Science, Inc. (US) | 2025-07-09 | — | — | EP | claimed |
| US-20240101510-A1 | APYRASE INHIBITORS | TEXAS CROP SCIENCE, INC. | 2024-03-28 | — | — | US | claimed |
| WO-2024050040-A2 | APYRASE INHIBITORS | TEXAS CROP SCIENCE (US) | 2024-03-07 | — | — | WO | claimed |
| US-20240101510-A1 | APYRASE INHIBITORS | TEXAS CROP SCIENCE, INC. | 2024-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240101510-A1 | APYRASE INHIBITORS | APEH, DPEP1, PON1 | NPC1 2564/4885RAB9A 1387/4885GAA 168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.